CL2020001402A1 - Derivados de imidazopiridina y su uso como medicamento. - Google Patents

Derivados de imidazopiridina y su uso como medicamento.

Info

Publication number
CL2020001402A1
CL2020001402A1 CL2020001402A CL2020001402A CL2020001402A1 CL 2020001402 A1 CL2020001402 A1 CL 2020001402A1 CL 2020001402 A CL2020001402 A CL 2020001402A CL 2020001402 A CL2020001402 A CL 2020001402A CL 2020001402 A1 CL2020001402 A1 CL 2020001402A1
Authority
CL
Chile
Prior art keywords
medicine
imidazopyridine derivatives
nr2b
treatments
prevention
Prior art date
Application number
CL2020001402A
Other languages
English (en)
Inventor
Dieter Wiedenmayer
Georg Dahmann
Riccardo Giovannini
Angelo Ceci
Cornelia Dorner-Ciossek
Lothar Kussmaul
Roland Pfau
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2020001402A1 publication Critical patent/CL2020001402A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyrane Compounds (AREA)

Abstract

La presente invención se refiere a imidazopiridinas novedosas de la Fórmula A, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en tratamientos, particularmente, en el tratamiento o prevención de afecciones que tienen una relación con las propiedades de modulación alostérica negativa de NR2B.
CL2020001402A 2017-12-08 2020-05-27 Derivados de imidazopiridina y su uso como medicamento. CL2020001402A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17206152 2017-12-08

Publications (1)

Publication Number Publication Date
CL2020001402A1 true CL2020001402A1 (es) 2020-09-21

Family

ID=60629568

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001402A CL2020001402A1 (es) 2017-12-08 2020-05-27 Derivados de imidazopiridina y su uso como medicamento.

Country Status (31)

Country Link
US (1) US10849907B2 (es)
EP (1) EP3720855B1 (es)
JP (1) JP6941235B2 (es)
KR (1) KR20200097301A (es)
CN (1) CN111344291B (es)
AR (1) AR113923A1 (es)
AU (1) AU2018379438B2 (es)
BR (1) BR112020008583A2 (es)
CA (1) CA3083331A1 (es)
CL (1) CL2020001402A1 (es)
CO (1) CO2020006648A2 (es)
CY (1) CY1124744T1 (es)
DK (1) DK3720855T3 (es)
EA (1) EA202091139A1 (es)
ES (1) ES2897050T3 (es)
HR (1) HRP20211726T1 (es)
HU (1) HUE056667T2 (es)
IL (1) IL274868B1 (es)
LT (1) LT3720855T (es)
MA (1) MA51020B1 (es)
MX (1) MX2020005869A (es)
PE (1) PE20211454A1 (es)
PL (1) PL3720855T3 (es)
PT (1) PT3720855T (es)
RS (1) RS62517B1 (es)
SA (1) SA520412155B1 (es)
SG (1) SG11202005138TA (es)
SI (1) SI3720855T1 (es)
TW (1) TWI809014B (es)
UA (1) UA126247C2 (es)
WO (1) WO2019110703A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020245137A1 (en) * 2019-06-04 2020-12-10 Boehringer Ingelheim International Gmbh Imidazopyrazine derivatives and the use thereof as medicament
TW202112378A (zh) * 2019-06-04 2021-04-01 德商百靈佳殷格翰國際股份有限公司 嘌呤衍生物及其作為藥物之用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495561B2 (en) 1999-10-29 2002-12-17 Merck & Co., Inc. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
IL159393A (en) 2001-07-24 2011-01-31 Richter Gedeon Vegyeszet Piperidine derivatives, pharmaceutical compositions containing them, processes for their preparation and uses thereof
US20110319416A1 (en) 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
AU2013333988B2 (en) 2012-10-18 2017-03-09 F. Hoffmann-La Roche Ag Ethynyl derivatives as modulators of mGluR5 receptor activity
JP6577479B2 (ja) 2014-02-27 2019-09-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｎａｖ チャンネル阻害剤としてのヘテロ環化合物及びその使用
US10030026B2 (en) * 2014-06-04 2018-07-24 Rugen Holdings (Cayman) Limited Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists
US10913736B2 (en) 2014-08-22 2021-02-09 University Of Washington Specific inhibitors of methionyl-tRNA synthetase
CN106715435B (zh) * 2014-09-15 2019-10-01 卢郡控股(开曼)有限公司 作为nr2b nmda受体拮抗剂的吡咯并嘧啶衍生物

Also Published As

Publication number Publication date
US20190175605A1 (en) 2019-06-13
HUE056667T2 (hu) 2022-02-28
LT3720855T (lt) 2021-11-10
CN111344291A (zh) 2020-06-26
MX2020005869A (es) 2020-09-09
SG11202005138TA (en) 2020-06-29
EP3720855B1 (en) 2021-08-25
TWI809014B (zh) 2023-07-21
MA51020B1 (fr) 2021-10-29
TW201936198A (zh) 2019-09-16
CA3083331A1 (en) 2019-06-13
EP3720855A1 (en) 2020-10-14
PE20211454A1 (es) 2021-08-05
IL274868A (en) 2020-07-30
MA51020A (fr) 2021-05-26
AU2018379438A1 (en) 2020-05-07
PL3720855T3 (pl) 2022-01-24
CY1124744T1 (el) 2022-07-22
PT3720855T (pt) 2021-11-03
JP6941235B2 (ja) 2021-09-29
WO2019110703A1 (en) 2019-06-13
ES2897050T3 (es) 2022-02-28
JP2021505584A (ja) 2021-02-18
CN111344291B (zh) 2023-05-05
AU2018379438B2 (en) 2022-08-18
US10849907B2 (en) 2020-12-01
SA520412155B1 (ar) 2022-06-05
EA202091139A1 (ru) 2020-11-23
BR112020008583A2 (pt) 2020-10-20
IL274868B1 (en) 2024-02-01
RS62517B1 (sr) 2021-11-30
KR20200097301A (ko) 2020-08-18
UA126247C2 (uk) 2022-09-07
HRP20211726T1 (hr) 2022-02-18
SI3720855T1 (sl) 2021-12-31
AR113923A1 (es) 2020-07-01
DK3720855T3 (da) 2021-11-08
CO2020006648A2 (es) 2020-06-09

Similar Documents

Publication Publication Date Title
ECSP20040257A (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
CO2018013978A2 (es) Derivados de ácido borónico y usos terapéuticos de los mismos.
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
CO7350655A2 (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
CL2015001864A1 (es) Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih.
CL2016000698A1 (es) Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih
SV2018005750A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue
CR20160006A (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
UY35142A (es) Derivados de triazolopirazinas como inhibidores de brd4
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
CO2018009563A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
UY35827A (es) Derivados de triazolopirazina como inhibidores de la proteína brd4
CL2019003398A1 (es) Inhibidores pirazólicos de magl.
BR112017003346B8 (pt) Derivados de pirazolopiridina, seus usos, e composição farmacêutica
AR099569A1 (es) Derivados de insulina y los usos médicos de estos
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
DOP2017000018A (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas
CL2020001402A1 (es) Derivados de imidazopiridina y su uso como medicamento.
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
CL2017000884A1 (es) Composición farmacéutica para usarse en el tratamiento o la prevención de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugía de derivación gástrica
CL2021000858A1 (es) Derivados de 4-pirazin-2-ilmetil-morfolina y su uso como medicamento
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação